'Interim data' presentation slideshows

Chapter 10 Data Monitoring, Monitoring Committee Function & Statistical Methods

Chapter 10 Data Monitoring, Monitoring Committee Function & Statistical Methods. Some References. Texts/Chapters 1. Friedman, Furberg & DeMets (1998) 3rd edition, Fundamentals of Clinical Trials, Springer-Verlag, NY, NY 2. Pocock (1983) Clinical Trials, Wiley.

1.3k views • 83 slides

Effective Use of Data and Goal Setting

791 views • 59 slides

Adaptive Designs Terminology and Classification Adaptive Seamless Phase II/III Designs

Adaptive Designs Terminology and Classification Adaptive Seamless Phase II/III Designs. Vlad Dragalin Global Biostatistics &Programming Wyeth Research. Co-Chairs: Michael Krams Brenda Gaydos Authors: Keaven Anderson Suman Bhattacharya Alun Bedding Don Berry Frank Bretz

1.29k views • 48 slides

Chapter 12

Chapter 12. Interim Reporting & Disclosures About Segments of an Enterprise. Interim Reporting. Provides information on a timely basis Affects the decision making process Views each interim period as an integral part of the annual period

563 views • 45 slides

Statistical Issues in Trial Reporting: Revised US FDA Regulations

Statistical Issues in Trial Reporting: Revised US FDA Regulations. David L DeMets, PhD Department of Biostatistics & Medical Informatics University of Wisconsin-Madison. Topics. 1. Clintrials.gov 2. Adverse Event Reporting 3. T2D Trial Design

412 views • 28 slides

DATA MONITORING COMMITTEES: COMMENTS ON PRESENTATIONS

DATA MONITORING COMMITTEES: COMMENTS ON PRESENTATIONS. Susan S. Ellenberg, Ph.D. Department of Biostatistics and Epidemiology University of Pennsylvania School of Medicine FDA/Industry Workshop Washington, DC September 28, 2006. CHANGING ROLE OF DMC. Increasing structure

265 views • 19 slides

ERA data

ERA data. Paul Berrisford Dick Dee, Paul Poli , Hans Hersbach , Carole Peubey , David Tan , Patrick Laloyaux , Takuya Komori, Rossana Dragani , Adrian Simmons. p.berrisford@reading.ac.uk. ERA@ECMWF. ERA home. ERA archive document. ECMWF data s erver.

299 views • 17 slides

CONFLICTS OF INTEREST ARE HERE TO STAY:

CONFLICTS OF INTEREST ARE HERE TO STAY:. PROTECTING SCIENCE FROM BIAS Susan S. Ellenberg, Ph.D. Center for Biologics Evaluation and Research, FDA Boston, MA May 3, 2004. CONFLICTS OF INTEREST IN SCIENCE. Conduct of research Entering, treating, evaluating patients Oversight of research

300 views • 9 slides

Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter,

Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial. Authors: Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group Reviewer: Dr. Chris Booth Date posted: December 12 2007.

225 views • 6 slides

PMX 2058 Efficacy: Panc-1 Xenografts (2)

180 views • 4 slides

PMX 2058 Efficacy: BxPC3 Xenografts (1)

198 views • 3 slides